Nuformix plc (LON:NFX – Get Free Report)’s stock price dropped 18% on Friday . The company traded as low as GBX 0.08 ($0.00) and last traded at GBX 0.08 ($0.00). Approximately 10,914,796 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 76,368,313 shares. The stock had previously closed at GBX 0.10 ($0.00).
Nuformix Price Performance
The business has a fifty day moving average of GBX 0.06 and a 200 day moving average of GBX 0.09. The stock has a market cap of £1.01 million, a PE ratio of -2.49 and a beta of 1.22.
Nuformix (LON:NFX – Get Free Report) last posted its quarterly earnings data on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Nuformix
- How to Choose Top Rated Stocks
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- The How and Why of Investing in Gold Stocks
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Invest in Small Cap Stocks
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
